Joint wear causes persistent pain, stiffness and reduced movement that can limit everyday activity. For people who want to avoid complex surgery, a single-step, non-surgical option is an understandably appealing starting point. This article sets out what the ChondroFiller injection involves, how it differs from multi-stage surgical treatments, and what the current evidence suggests — with realistic expectations throughout.

What Is ChondroFiller and How Does It Work?

ChondroFiller is a Class III CE-marked medical device: an acellular (cell-free) type I collagen hydrogel scaffold manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. Because the device contains no cells, it requires no harvesting or laboratory processing of the patient's own tissue.

When injected, the liquid collagen component gels within approximately three to five minutes at body temperature, filling the contour of the worn or damaged area. The resulting scaffold acts as a chemotactic matrix, recruiting the patient's own progenitor cells from the surrounding synovium and subchondral bone to migrate into the defect, differentiate into chondrocyte-like cells and begin synthesising new cartilage matrix. The implant is gradually resorbed over one to two years as this repair tissue matures.

In clinical practice, ChondroFiller is delivered as an ultrasound-guided outpatient injection — no theatre, no general anaesthetic, and no incision. This is what distinguishes it from surgical cartilage repair: it is a non-surgical procedure suited to accessible joints and appropriately selected lesions.

How It Compares with Traditional Treatments

Conventional cartilage repair techniques such as autologous chondrocyte implantation (ACI) or osteochondral grafting typically involve two or more stages: an initial harvest procedure, a period of cell culture or graft preparation, and a second operation to implant the repair. These approaches carry theatre risk, longer recovery, and greater procedural burden.

ChondroFiller, by contrast, is a single-step procedure. The entire treatment is delivered in one outpatient session, without cell harvesting or a second operation. It is best understood as a supportive, joint-preserving intervention — it provides a regenerative scaffold and may reduce symptoms in suitable patients, but it is not a cure for osteoarthritis and does not reverse established joint degeneration.

For patients with larger or more complex cartilage defects, or where lesion access requires direct visualisation, a surgical approach may be more appropriate. In those situations, the Liquid Cartilage protocol — Professor Paul Y. F. Lee's keyhole surgical technique, which places the ChondroFiller scaffold arthroscopically alongside biological adjuncts — is a distinct and separate pathway from the injection. A specialist assessment determines which option, if any, is indicated.

What the Evidence Shows

The evidence base for ChondroFiller as a device continues to develop. Clinical evaluation data across multiple joints shows meaningful improvements in patient-reported outcomes: in knee studies, International Knee Documentation Committee (IKDC) scores have improved by approximately 30 points over 12 to 36 months, and in hip studies, modified Harris Hip Scores (mHHS) have improved by more than 30 points. Magnetic resonance imaging-based MOCART scores in published series are around 80 and above, indicating substantial defect fill and repair-tissue quality.

For smaller joints, a 2023 study of an acellular collagen matrix injection for thumb-base (trapeziometacarpal) osteoarthritis reported improvements in pain scores and grip strength (Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U., 2023, The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis, Cartilage). Across more than 19,000 units sold since 2013, the device has an exceptionally low reported complication rate.

Responses depend on the degree and location of wear, patient age, overall joint health, and other individual factors. Benefits cannot be guaranteed, and not everyone will be a suitable candidate.

Who May Be Suitable?

The ChondroFiller injection is generally considered for patients with ICRS Grade I to IV cartilage defects up to a certain size in accessible joints, including the knee, hip, ankle, shoulder and hand. Suitability depends on a thorough clinical assessment including imaging, and is not determined by symptoms alone.

People who are not appropriate candidates for theatre — because of age, comorbidities, or personal preference — may find a non-surgical injection a worthwhile option to discuss with a specialist. Equally, it is not a substitute for joint replacement in advanced disease, and a clinician will advise honestly on realistic expectations.

A Note on Next Steps

At the London Cartilage Clinic on Harley Street, specialist assessment considers the full picture: imaging, symptom history, activity level and patient priorities. Where the ChondroFiller injection is appropriate, it can often be planned promptly. Where a surgical approach is better suited, that option will be explained clearly.

Anyone considering the injection for joint wear should seek a specialist consultation to understand whether it is appropriate for their specific situation — this article is intended as background information, not a clinical recommendation.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.